ILMN

Illumina Inc (ILMN)

$134.87

Last Close (24-hour delay)

Profit since last BUY12.4%

Consider higher Upturn Star rating

BUY since 29 days

• BUY Advisory
• SELL Advisory (Profit)
• SELL Advisory (Loss)

• Profit
• Loss
• Pass (Skip investing)

Stock price based on last close

*as per simulation
(see disclosures)

Upturn Star Rating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Number of Analysts

25 Analysts rated it

Well-followed company, solid analyst reports, reliable data for confident investing.

Analysis of Past Performance

Type Stock

Historic Profit 34.74%

Avg. Invested days 51

Today’s Advisory Consider higher Upturn Star rating

Upturn Star Rating

Upturn Advisory Performance 5.0

Stock Returns Performance 3.0

Profits based on simulation

Last Close 12/12/2025

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.